文献速递心力衰竭与心肌病

达格列净对心衰全射血分数谱患者特异性死亡率的影响:DAPA-HF与DELIVER汇总分析

Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVER.
PubMed 文献 · JAMA Cardiol · 2022-01-01

IMPORTANCE: In 2 trials enrolling patients with heart failure (HF) across the spectrum of ejection fraction (EF), dapagliflozin has been shown to reduce the rate of the composite of worsening HF events or death from cardiovascular (CV) causes.…

要点

  • 达格列净显著降低全射血分数谱心衰患者的心血管死亡风险(HR 0.86, 95%CI 0.75-0.98)。
  • 心血管死亡减少主要来自猝死(HR 0.84)和心衰死亡(HR 0.88)的数值降低。
  • 非心血管死亡比例随射血分数升高而增加,达格列净对卒中或心梗死亡影响不大。

核心结论

  • 在DAPA-HF和DELIVER试验的汇总分析中,达格列净在全LVEF谱心衰患者中显著降低心血管死亡风险,主要由猝死和进行性心衰死亡减少驱动。

研究设计与样本

  • 参与者水平、汇总、预设的二次分析,汇总DAPA-HF(LVEF≤40%)和DELIVER(LVEF>40%)两项随机对照试验。

主要发现

  • 随访期间共发生1628例死亡,其中872例(53.5%)为心血管死亡,487例(29.9%)为非心血管死亡,269例(16.5%)为未确定原因。
  • 心血管死亡中,心衰死亡289例(33.1%),猝死441例(50.6%),卒中死亡69例(7.9%),心梗死亡47例(5.4%),其他心血管死亡26例(3.0%)。

临床怎么用

  • 对于慢性心衰患者,无论射血分数高低,达格列净治疗可降低心血管死亡风险,尤其可能减少猝死和心衰死亡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In 2 trials enrolling patients with heart failure (HF) across the spectrum of ejection fraction (EF), dapagliflozin has been shown to reduce the rate of the composite of worsening HF events or death from cardiovascular (CV) causes. OBJECTIVE: To examine the effects of dapagliflozin on cause-specific CV and non-CV mortality across the spectrum of EF. DESIGN, SETTING, AND PARTICIPANTS: This was a participant-level, pooled, prespecified secondary analysis of data from the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure, or DAPA-HF trial (participant left ventricular EF [LVEF] ≤40%), and Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure, or DELIVER trial (participant LVEF >40%), to assess the effects of randomized treatment on cause-specific mortality. The trials assigned adjacent populations of patients with chronic HF, New York Heart Association class II-IV symptoms, and elevated natriuretic peptides to treatment with dapagliflozin (10 mg, once daily) or placebo. The primary outcome for each study was a composite of worsening HF events (hospitalization or urgent heart failure visits) or CV death. Clinical outcomes, including all deaths, were adjudicated as to cause by clinical end points committees blinded to treatment assignment. INTERVENTION: Dapagliflozin vs placebo. MAIN OUTCOMES AND MEASURES: The mode of death in relation to baseline EF was examined, as well as the effect of randomized treatment on cause-specific death in Cox regression models. Relationships with continuous EF were modeled using Poisson regression. RESULTS: Of 11 007 patients in the pooled data set, there were 1628 deaths during follow-up (mean [SD] age, 71.7 [10.3] years; 1139 male [70.0%]). Of those who died, 872 (53.5%) were ascribed to CV deaths, 487 (29.9%) to non-CV deaths, and 269 (16.5%) to undetermined causes. Of CV deaths, 289 (33.1%; this represented 17.8% of total deaths) were due to HF, 441 (50.6%; 27.1% of total deaths) were sudden, 69 (7.9%; 4.2% of total deaths) were due to stroke, 47 (5.4%; 2.9% of total deaths) to myocardial infarction, and 26 (3.0%; 1.6% of total deaths) were due to other CV causes. The proportion of non-CV deaths was higher in those with higher EF. In the pooled population, across the spectrum of EF, treatment with dapagliflozin was associated with lower rates of CV death (hazard ratio [HR], 0.86; 95% CI, 0.75-0.98; P = .02), principally due to lower rates of sudden death (HR, 0.84; 95% CI, 0.70-1.01; P = .07) and HF death (HR, 0.88; 95% CI, 0.70-1.11; P = .30), with little difference in rates of death from stroke or MI. CONCLUSIONS AND RELEVANCE: In a pooled analysis of patients with HF in the DAPA-HF and DELIVER randomized clinical trials, across the full spectrum of LVEF, dapagliflozin significantly reduced risks of CV death with contributions from lower rates of sudden death and death from progressive HF. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03036124, NCT03619213.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Desai, Jhund, Claggett, et al. Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVER. JAMA Cardiol. 2022. PMID: 36189985. doi:10.1001/jamacardio.2022.3736

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。